Physician profile
Dina White
NPI 1922061548
$7,392.39
in general payments reported to CMS, 2019-2025
50 companies · $1,098 in 2025
The $1,098 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $707 · 2020: $600 · 2021: $1,120 · 2022: $1,311 · 2023: $1,396 · 2024: $1,160 · 2025: $1,098.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,637 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,637.33 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $953.18 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $804.43 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $694.88 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $632.85 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $571.25 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $420.62 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $343.19 | 2021-2025 | |
| Pfizer INC. | $261.61 | 2019-2025 | |
| Caldera Medical, INC | $200.26 | 2023 | Desara |
| Amarin Pharma, INC. | $199.92 | 2019-2022 | |
| Antares Pharma, INC. | $193.65 | 2020-2025 | Xyosted, Tlando, Nocdurna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.38 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $142.48 | 2021-2025 | Veozah |
| Allergan, INC. | $135.65 | 2020 | |
| Eisai INC. | $116.75 | 2020-2022 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dina White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.